Zealand Pharma expands management team

Danish biopharmaceutical firm makes three senior appointments

Danish biopharmaceutical company Zealand Pharma has appointed Christian Grondahl as chief scientific officer, Mats Blom as chief financial officer and John Hyttel as senior vice president for operations.

"Together they bring a wealth of experience, energy and skills to Zealand Pharma as we continue to advance our growth strategy," said David Horn Solomon, chief executive of Zealand Pharma.

Grondahl starts on 1 April, joining the firm from Novo Nordisk, where until recently he was corporate vice president for strategic alliances.

Blom, who joined the company earlier this month, was cfo of Swedish Orphan International, which recently merged with Biovitrum to form Swedish Orphan-Biovitrum of Stockholm.

Hyttel, who became senior vice president for operations on 1 March, founded Zealand Pharma in 1998. He worked for H Lundbeck for 30 years prior to joining Zealand.

Zealand's most advanced project, Lixisenatide (ZP10/AVE0010), a GLP-1 agonist for the treatment of Type II diabetes has been out licensed to Sanofi-Aventis of France. Sanofi-Aventis is completing 9 Phase III trials with first results to be released in June. Sanofi-Aventis is also commercialising a Lantus-Lixisenatide combination product for the treatment of Type II diabetes that has completed Phase I clinical studies. Submission of IND/MAA for Lixisenatide is expected in 2011.

You may also like

Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

L.B. Bohle hosts successful continuous manufacturing workshop in Brazil

Focus on continuous wet granulation and drying for research, development and small-scale production
Manufacturing

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development

Lonza to provide cGMP manufacturing and technical support to advance bimiralisib into late-stage clinical development
Research & Development

Phesi analysis finds 6.7% of global clinical trials affected by Middle East disruption

A Phesi analysis of more than 65,000 active clinical trials has found that 4361 studies are impacted by Middle East disruption, with Phase III oncology trials most exposed and all top ten global pharma companies holding significant investigator site presence in affected countries
Regulatory

FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions

Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Pharmaceutical

Tekpak Automation to showcase pharma pick-and-place robotic cell at interpack 2026

Tekpak Automation will demonstrate the benefits of robotics for pharmaceutical applications at interpack 2026, with a LIVE working demonstration of a 3-axis pick-and-place cell handling medipens on Stand A15/Hall 16
Regulatory

FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths

The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Subscribe now